Johnson & Johnson closed $26.58 below its 52-week high ($168.85), which the company reached on September 4th.

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Fast Track designation to posdinemab, a phosphorylated ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on January 6 and set a price ...

The jury determined that Johnson & Johnson was negligent and that the company intentionally misrepresented the safety of its ...

Johnson & Johnson closed $22.62 below its 52-week high ($168.85), which the company achieved on September 4th.

In recent years treatment with powerful biologic and targeted synthetic therapies has changed the landscape for arthritis, but currently finding the right treatment for each person is a matter of ...

The department store is bringing back its cursive logo at a time when many brands are ditching script. Lord & Taylor is going ...

Cursive logos were all but declared dead in 2024 after even Johnson & Johnson ditched its iconic script logotype, ...

Without a speaker, lawmakers cannot formally certify Donald Trump's win, raising personal stakes for the president-elect to ...

From 'high gloss' to more craft in the design process, these are what designers want to see more of next year.

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...